Clinical trials: RNA Profile
Influenza Immunization, Healthy Volunteers
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older
Primary Objective: To demonstrate that high-dose quadrivalent influenza vaccine (QIV-HD) induces an immune response that is superior to the responses induced by standard-dose quadrivalent influenza vaccine (QIV-SD) for all 4…
- Trial name
- NCT04024228
- Testing
- Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD), High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation
- Where
- 17 sites in Belgium, France and 4 more
- Volunteers
- 1,539 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza (Healthy Volunteers)
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older
Primary Objective: Immunogenicity: To describe the immune response induced by high-dose quadrivalent influenza vaccine (QIV-HD) and AdimFlu-S (QIS) by hemagglutinin inhibition (HAI) measurement method in all participants.
- Trial name
- NCT04537234
- Testing
- High-Dose Quadrivalent Influenza Vaccine, Standard-Dose Quadrivalent Influenza Vaccine
- Where
- 4 sites in Taiwan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults
This study will assess the Efficacy, Safety and Tolerability profile of CSL's Influenza Vaccine administered intramuscularly against laboratory-confirmed influenza illness in a population defined as being not at risk of severe…
- Trial name
- CSL's IVV (NCT00562484)
- Testing
- CSL Limited Influenza Vaccine
- Where
- 24 sites in Australia, New Zealand
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Seqirus
Non-Small Cell Lung Cancer, Metastatic Melanoma
A Study to Investigate 14C-bemcentinib in Healthy Male Subjects
The aims of this Study were to determine: How much of the Study Drug (bemcentinib) ends up in urine and faeces How much of the Study Drug and its breakdown products get into the bloodstream The breakdown products (metabolites) of…
- Conditions
- Non-Small Cell Lung Cancer, Metastatic Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- 8479217 (NCT06469138)
- Testing
- Bemcentinib
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- BerGenBio ASA
Covid19
Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19
An early stage trial to check how safe and tolerable, as well as how the body handles continuous daily use of Active IMP over 28 days in healthy volunteers.
- Trial name
- NCT04632706
- Testing
- Ivermectin
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- MedinCell S.A
Influenza
A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population
The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US licensed comparator Influenza Virus Vaccine in a pediatric population aged greater than or…
- Trial name
- NCT00959049
- Testing
- CSL's Influenza Virus Vaccine (Afluria), Influenza Virus Vaccine (Fluzone)
- Where
- 23 sites in United States
- Volunteers
- 1,474 people, healthy volunteers welcome
- Sponsor
- Seqirus
HIV Infections
The Raltegravir and Ribavirin Pharmacokinetics (PK) Study
The purpose of this study is to look at levels of both a new anti-HIV drug called raltegravir and an existing anti-hepatitis C drug called ribavirin to see if they affect the blood levels of each other when given separately and…
- Trial name
- NCT00982553
- Testing
- Ribavirin, Raltegravir
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Influenza
A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine
The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US Licensed Comparator Influenza Virus Vaccine.
- Trial name
- NCT00735475
- Testing
- CSL Limited Influenza Virus Vaccine (Afluria®), US Licensed Influenza Virus Vaccine (Fluzone®)
- Where
- 13 sites in United States
- Volunteers
- 1,268 people, healthy volunteers welcome
- Sponsor
- Seqirus
Hepatitis C
The Boceprevir and Sildenafil Pharmacokinetics Study
This is a healthy volunteer study looking at the interactions between two drugs: boceprevir and sildenafil. New drugs are being developed to treat people with the chronic viral infection hepatitis C.
- Trial name
- NCT01499498
- Testing
- Sildenafil and Boceprevir
- Where
- United Kingdom
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Influenza Immunization, Healthy Volunteers
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older
Primary Objective: To demonstrate that QIV-HD induced an immune response (as assessed by hemagglutination inhibition [HAI] geometric mean titers [GMTs] and seroconversion rates) that was superior to responses induced by QIV-SD…
- Trial name
- NCT04498832
- Testing
- High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD), Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)
- Where
- 10 sites in Japan
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company